ClearArc Capital’s Teva Pharmaceuticals TEVA Stock Holding History

ClearArc Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-12,629	Closed	-$713K	–	448
2015 Q3	$713K	Sell	12,629 -3,794	-23%	-$246K	0.15%	180
2015 Q2	$971K	Sell	16,423 -22	-0.1%	-$1.36K	0.18%	153
2015 Q1	$1.02M	Sell	16,445 -3,429	-17%	-$199K	0.21%	137
2014 Q4	$1.14M	Buy	19,874 +2,206	+12%	+$123K	0.23%	132
2014 Q3	$950K	Buy	17,668 +2,057	+13%	+$109K	0.21%	139
2014 Q2	$818K	Buy	15,611 +544	+4%	+$27.8K	0.19%	151
2014 Q1	$796K	Sell	15,067 -1,285	-8%	-$59.4K	0.2%	146
2013 Q4	$655K	Buy	16,352 +2,851	+21%	+$112K	0.17%	165
2013 Q3	$510K	Buy	13,501 +4,872	+56%	+$190K	0.14%	179
2013 Q2	$338K	Buy	+8,629	New	+$336K	0.09%	247

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

ClearArc Capital's TEVA Position: Q4 2015 in Review

ClearArc Capital sold out of Teva Pharmaceuticals (TEVA) in Q4 2015, closing a stake of 12,629 shares — an estimated $713K sold.

ClearArc Capital first reported a position in TEVA in Q2 2013 and held it in 10 quarters. The position peaked at $1.14M in Q4 2014. 876 funds tracked by Wall St. Rank hold TEVA as of Q4 2015.

ClearArc Capital reported no remaining Teva Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
ClearArc Capital sold 12,629 Teva Pharmaceuticals shares in Q4 2015, an estimated $713K.
ClearArc Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 10 quarters.
ClearArc Capital's Teva Pharmaceuticals position peaked at $1.14M in Q4 2014.
876 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2015.

Based on ClearArc Capital's 13F filing for Q4 2015, filed 12 Feb 2016.